Ariceum Therapeutics
Ariceum Therapeutics (Ariceum) is a private biotech company developing a novel, first in class radiopharmaceutical product for the diagnosis and targeted radiotherapy of certain hard-to-treat cancers.
Ariceum Therapeutics has raised €25M across 1 funding round from 3 investors, most recently a Series A round in Jun 2022. Based in Berlin, Germany; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€25M
€25,000,000
Funding rounds
1
Investors
3
distinct backers
Active since
2022-06
latest 2022-06
Funding by year
EUR raised per yearAriceum Therapeutics — funding by year — interactive chart.
Data table
| Ariceum Therapeutics — funding by year | |
|---|---|
| 2022 | €25M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Series A
- ▼ Past typical raise window
- ▼ Low backer re-investment
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-06-10 | Series A | €25M | EQT Life Sciences,HealthCap,Ipsen Pharma | View deal → |
Investors
3Related news
Similar companies
same sector or country- Delivery Hero€7.1BGermany · E-commerce
- Enpal€4.6BGermany · Cleantech
- Auxmoney€3.5BGermany · Fintech
- Helsing€2.9BGermany · AI
- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
Global coverage: FundingData